Nasdaq · Healthcare

RHYTHM PHARMACEUTICALS, INC. (RYTM)

As-reported financials and recent SEC filings for RHYTHM PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$189.8M

Net income

$-196.5M

Net margin

-103.6%

Diluted EPS

$-3.11

ROE

-141.3%

P/E (TTM)

—

Market cap

—

Debt / equity

0.7×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$189.8M	$130.1M	$77.4M	$23.6M	$3.2M
Gross profit	$170.3M	$116.8M	$68.1M	$21.5M	$2.6M
Operating income	$-192.0M	$-265.5M	$-184.4M	$-179.2M	$-170.1M
Net income	$-196.5M	$-260.6M	$-184.7M	$-181.1M	$-69.6M
Diluted EPS	$-3.11	$-4.34	$-3.20	$-3.47	$-1.40

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

8-K2026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-24

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on RYTM

Search RHYTHM PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.